retatrutide gip glp-1 glucagon receptor agonist Retatrutide, a GIP, and agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA retatrutide triple hormone receptor agonist

The purpose of this paper is to critically examine the inconsistencies of currently published data, examine the appropriateness of the current guidelines and to further educate anesthesiologists on the importance of informed perioperative assessment and management of these patients

J., Parkes, D., Feigh, M., Suschak, J

Current demand for the mediation is outpacing production

Immunol Cell Biol (2008) 86(8):6508

The efficacy of liraglutide on weight management was subsequently surpassed by semaglutide, which, when administered weekly at a dose of 2.4 mg in obese patients without diabetes, resulted in a weight reduction of 12.4% compared to placebo in the STEP 1 study [46], and a reduction of 9.4% compared to liraglutide 3.0 mg in the STEP-8 study [47]

for clinical use in this class: sitagliptin, linagliptin, saxagliptin plus vildagliptin in Europe